Institut für Herzinfarktforschung Ludwigshafen an der Universität Heidelberg, Ludwigshafen, Germany.
Clin Res Cardiol. 2011 Apr;100(4):277-87. doi: 10.1007/s00392-010-0240-9. Epub 2010 Oct 21.
According to various national and international guidelines, the target LDL-C level is <100 mg/dl for patients with established coronary heart disease (CHD) or CHD risk equivalent (CE). We aimed to investigate aspects of the lipid-lowering management of patients at high cardiovascular risk in-hospital care and the achievement of target values.
In the internet-based 2L registry in Germany (2005-2006), cardiologists in 42 hospitals documented at a single visit 3,131 consecutive patients with known CHD, and/or diabetes mellitus, peripheral arterial disease, or a 10-year CHD risk >20% (summarized as CE), who were on chronic statin treatment. They received instructions on the guidelines and instant feedback on the effect of their treatment decisions (educational study component).
The three groups comprised 1,458 patients with CHD + CE (46.6%; median LDL-C 107 mg/dl), 1,104 patients with CHD only (35.3%; median LDL-C 104 mg/dl), and 569 with CE only (18.2%; median LDL-C 111 mg/dl). At admission, LDL-C levels <100 mg/dl were observed in 43.1, 44.8 and 37.9% of patients in the three groups, respectively. Statin doses at admission were usually in the low to intermediate range (e.g., simvastatin 10-20 mg/day). Cardiologists switched to another statin in 14.6%, increased the dose of statins (if same drug) in 22.9% (mean increase from 26.8 mg/day at baseline to 31.6 mg/day) and/or added a cholesterol absorption inhibitor (CAI) in 11.6%. The cardiologists' intervention improved estimated LDL-C levels (using a lipid calculator); however, the 100 mg/dl LDL-C target was only reached in 49.0, 48.5, and 42.9%.
When compared with earlier studies in the outpatient setting, the treatment to target for LDL-C of high-risk CHD patients has improved, but is not satisfactory.
根据各国和国际指南,确诊冠心病(CHD)或冠心病等同症(CE)患者的 LDL-C 目标值应<100mg/dl。本研究旨在调查住院高心血管风险患者的降脂治疗管理方面,以及目标值的达标情况。
在德国的基于互联网的 2L 注册研究(2005-2006 年)中,42 家医院的心脏病专家在一次就诊时记录了 3131 例连续的已知 CHD 患者和/或糖尿病、外周动脉疾病或 10 年 CHD 风险>20%(概述为 CE)的患者,这些患者正在接受慢性他汀类药物治疗。他们接受了指南的指导,并即时反馈其治疗决策的效果(教育研究部分)。
三组分别为 1458 例 CHD+CE(46.6%;中位数 LDL-C 107mg/dl)、1104 例仅 CHD(35.3%;中位数 LDL-C 104mg/dl)和 569 例仅 CE(18.2%;中位数 LDL-C 111mg/dl)。入院时,三组患者的 LDL-C<100mg/dl 的比例分别为 43.1%、44.8%和 37.9%。入院时他汀类药物剂量通常处于低至中等范围(例如,辛伐他汀 10-20mg/天)。14.6%的心脏病专家换用了另一种他汀类药物,22.9%增加了他汀类药物的剂量(如果使用同一种药物)(平均从基线时的 26.8mg/天增加到 31.6mg/天),11.6%的心脏病专家加用了胆固醇吸收抑制剂(CAI)。心脏病专家的干预措施改善了估计的 LDL-C 水平(使用脂质计算器);然而,仅 49.0%、48.5%和 42.9%的患者达到了 100mg/dl 的 LDL-C 目标值。
与门诊环境下的早期研究相比,高危 CHD 患者的 LDL-C 靶向治疗有所改善,但仍不理想。